



## Brisdelle<sup>®</sup> (paroxetine mesylate) – First-time generic

- On September 18, 2017, Solco Healthcare, the U.S. sales and marketing division of Princeton Pharmaceutical, launched an AB-rated generic version of Sebel's Brisdelle (paroxetine mesylate) 7.5 mg capsules.
- Brisdelle is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.
  - Brisdelle is not indicated for the treatment of any psychiatric condition.
  - Brisdelle contains a lower dose of paroxetine than that used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. The safety and efficacy of this lower dose of paroxetine in Brisdelle have not been established for any psychiatric condition. Patients who require paroxetine for treatment of a psychiatric condition should discontinue Brisdelle and initiate a paroxetine-containing medication that is indicated for such use.
- Brisdelle carries a boxed warning for suicidal thoughts and behaviors.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.